New inhaled therapy targets Hard-to-Treat cystic fibrosis mutation
Disease control
Recruiting now
This study tests an experimental inhaled drug called SPL84 in adults with cystic fibrosis who have a specific genetic mutation (3849+10kb C->T). The main goal is to check if the drug is safe and tolerable, and to see early signs it might work. About 64 participants will receive e…
Phase: PHASE2 • Sponsor: SpliSense Ltd. • Aim: Disease control
Last updated May 18, 2026 03:51 UTC